BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is a biotechnology company with a strong pipeline of novel small-molecule drugs targeting various therapeutic areas. Its main product, Orladeyo, has shown consistent growth and the recent launch of its pediatric pellet formulation presents significant upside for future revenue. The company also has multiple milestones coming up, including potential positive data from competitor PHVS and the launch of its drug navenibart. The recent decision to focus on rare disease pipeline expansion while reducing expenses reflects a more strategic use of capital and has the potential to lead to long-term profitability. However, delays in Orladeyo growth or competition from new drug launches could pose risks to the company's future success.

BioCryst Pharma is facing limited adjustments following the 2Q26 update and reduced Orladeyo estimates in FY26. Despite a positive bias on BCRX, the net of these changes yields a new $20 target on shares which is primarily driven by Orladeyo forecasts, while the pending addition of navenibart serves as the potential upside in the company's HAE franchise. If successful, navenibart could also provide a sustained revenue stream with the potential for both 3- and 6-month dosing. However, there are key clinical risks, such as the Netherton Syndrome program and the potential failure of avoralstat in DME patients, that could significantly impact the company's growth prospects.